article thumbnail

The Cutaneous Connection: Pearls for Atopic Dermatitis in College-Aged Patients

Dermatology Times

In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management.

article thumbnail

Eczema (Atopic Dermatitis) vs. Psoriasis: Understanding the Differences

First Derm

Different Triggers and Causes : Eczema flare-ups can be triggered by allergens and irritants, whereas psoriasis can be exacerbated by stress, infections, and certain medications. Contact dermatitis from metals, latex, chemicals. Medications (lithium, beta-blockers, NSAIDs). 2] Why is Eczema Considered a Chronic Condition?

Eczema 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference?

First Derm

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

article thumbnail

Important Updates on the Efficacy and Safety of JAK Inhibitors in Dermatology

The Dermatology Digest

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, reviews the latest efficacy and safety data on oral and topical Janus kinase (JAK) inhibitors used in dermatology. He spoke on this topic at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference.

Safety 74
article thumbnail

Amytrx Publishes Abstract Supporting AMTX-1000 to Treat Mild to Moderate Atopic Dermatitis

MedEsthetics

atopic dermatitis, acne, inflammatory conditions, skincare, acne treatment, peptide, medical aesthetics, clinical trials, phase 1 study, British journal of dermatology

article thumbnail

Arcutis’ Zoryve Foam Is Now Available for Seb Derm Treatment in the U.S.

The Dermatology Digest

s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. Arcutis Biotherapeutics, Inc.’s

article thumbnail

Rethinking Dermatitis Diagnosis and Treatment 

The Dermatology Digest

Daniel Butler discusses strategies for diagnosing atypical dermatitis and overcoming medication access issues, including the use of alternative metrics to measure disease severity, practicing physician patience, and learning to navigate the payer system. We are so reliant on our physical exam skills [and] appropriately so. “And